The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
Open accessAbstract
BACKGROUNDCoronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Antiviral immune response is crucial to achieve pathogen clearance; however, in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, and pathology is essential to better characterize disease progression and widen the spectrum of therapeutic options.METHODSWe performed a flow cytometric characterization of immune cell subsets from 30 patients with COVID-19 and correlated these data with clinical outcomes.RESULTSPatients with COVID-19 showed decreased numbers of circulating T, B, and NK cells and exhibited a skewing of CD8+ T cells toward a terminally differentiated/senescent phenotype. In agreement, CD4+ T and CD8+ T, but also NK cells, displayed reduced antiviral cytokine production capability. Moreover, a reduced cytotoxic potential was identified in patients with COVID-19, particularly in those who required intensive care. The latter group of patients also showed increased serum IL-6 levels that inversely correlated to the frequency of granzyme A-expressing NK cells. Off-label treatment with tocilizumab restored the cytotoxic potential of NK cells.CONCLUSIONThe association between IL-6 serum levels and the impairment of cytotoxic activity suggests the possibility that targeting this cytokine may restore antiviral mechanisms.FUNDINGThis study was supported by funds from the Department of Experimental and Clinical Medicine of University of Florence (the ex-60% fund and the "Excellence Departments 2018-2022 Project") derived from Ministero dell'Istruzione, dell'Università e della Ricerca (Italy).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For CD8+ T cells, there are reports of diminished CD8+ cytotoxicity and cytokine production in severe cases126,132, while others report the opposite141, and still others find no differences142.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [142]
In the citing paper
“Some studies have found reduced effector functions for CD4+ T cells, i.e. IFNγ/IL-2/TNFα production, in patients with severe disease141, while others have seen no differences142.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [142]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,745
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 505
Continuous tracking of COVID-19 patients' immune status
Guan, J., Wei, X., Qin, S., Liu, X., Jiang, Y., Chen, Y., Chen, Y., Lu, H., Qian, J., Wang, Z., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107034 · Cited by 49
Meyerowitz, E. A., Sen, P., Schoenfeld, S. R., Neilan, T. G., Frigault, M. J., Stone, J. H., Kim, A. Y., & Mansour, M. K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1759 · Cited by 47
The crucial role of prolactin-lactogenic hormone in Covid-19
Al-Kuraishy, H. M., Al-Gareeb, A. I., Butnariu, M., & Batiha, G. E. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04381-9 · Cited by 46
Immune checkpoint inhibition in COVID-19: risks and benefits
Pezeshki, P. S., & Rezaei, N. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1887131 · Cited by 43
Popescu, I., Snyder, M. E., Iasella, C. J., Hannan, S. J., Koshy, R., Burke, R., Das, A., Brown, M. J., Lyons, E. J., Lieber, S. C., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202111-2493oc · Cited by 46
Çınar, T., Hayıroğlu, M. İ., Çiçek, V., Kılıç, Ş., Asal, S., Yavuz, S., Selçuk, M., Yalçınkaya, E., Keser, N., & Orhan, A. L. (2021) · Heart & Lung · doi:10.1016/j.hrtlng.2021.01.006 · Cited by 42
Hasenkrug, K. J., Feldmann, F., Myers, L. M., Santiago, M. L., Guo, K., Barrett, B. S., Mickens, K. L., Carmody, A., Okumura, A., Rao, D., et al. (2021) · mBio · doi:10.1128/mbio.01503-21 · Cited by 40
Multiomics: unraveling the panoramic landscapes of SARS-CoV-2 infection
Wang, X., Xu, G., Liu, X., Liu, Y., Zhang, S., & Zhang, Z. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00754-0 · Cited by 42
Tom, J. A., Bao, M., Tsai, L. W., Qamra, A., Summers, D. M., Carrasco‐Triguero, M., McBride, J., Rosenberger, C. M., Lin, C. J. F., Stubbings, W. J., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005229 · Cited by 41
Lamacchia, G., Mazzoni, A., Spinicci, M., Vanni, A., Salvati, L., Peruzzi, B., Bencini, S., Capone, M., Carnasciali, A., Farahvachi, P., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01325-2 · Cited by 43
Self-citationKumar, V. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106980 · Cited by 42
Rodríguez-Serrano, D. A., Roy‐Vallejo, E., Cruz, N. D. Z., Ramírez, A. M., Rodríguez-García, S. C., Arevalillo-Fernández, N., Galván‐Román, J. M., García–Rodrigo, L. F., Vega‐Piris, L., Llano, M. C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92497-1 · Cited by 41
Jung, H. E., & Lee, H. K. (2021) · Viruses · doi:10.3390/v13112132 · Cited by 43
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
Alunno, A., Najm, A., Machado, P., Bertheussen, H., Burmester, G. R., Carubbi, F., Marco, G. D., Giacomelli, R., Hermine, O., Isaacs, J. D., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219724 · Cited by 40
Heterogenous CD8+ T Cell Maturation and ‘Polarization’ in Acute and Convalescent COVID-19 Patients
Kudryavtsev, I. V., Arsentieva, N. A., Korobova, Z. R., Isakov, D., Rubinstein, A., Batsunov, O. K., Khamitova, I. V., Kuznetsova, R. N., Валерьевич, С. Т., Akisheva, T., et al. (2022) · Viruses · doi:10.3390/v14091906 · Cited by 56
Immune memory in convalescent patients with asymptomatic or mild COVID-19
Long, Q., Jia, Y., Wang, X., Deng, H., Cao, X., Yuan, J., Fang, L., Cheng, X.-R., Luo, C., He, A.-R., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00250-9 · Cited by 41
On the genetics and immunopathogenesis of COVID-19
Jacob, C. O. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108591 · Cited by 39
How could we forget immunometabolism in SARS-CoV2 infection or COVID-19?
Kumar, V. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2020.1840567 · Cited by 39
The role of HMGB1 in COVID‐19‐induced cytokine storm and its potential therapeutic targets: A review
Wulandari, S., Hartono, H., & Wibawa, T. (2022) · Immunology · doi:10.1111/imm.13623 · Cited by 38
Coronavirus disease 2019 (COVID-19) and autoimmunity
Nasonov, E. L. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-5-30 · Cited by 41
Vascular Alterations Following COVID-19 Infection: A Comprehensive Literature Review
Karakasis, P., Nasoufidou, A., Sagris, Μ., Fragakis, N., & Tsioufis, K. P. (2024) · Life · doi:10.3390/life14050545 · Cited by 37
Severe SARS-CoV-2 disease in the context of a NF-κB2 loss-of-function pathogenic variant
Abraham, R. S., Marshall, J. M., Kuehn, H. S., Rueda, C. M., Gibbs, A., Guider, W., Stewart, C. A., Rosenzweig, S. D., Wang, H., Jean, S., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.09.020 · Cited by 38
Liao, B., Liu, Z.-P., Tang, L.-B., Li, L., Gan, Q., Shi, H., Jiao, Q., Guan, Y., Xie, M., He, X., et al. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.49728 · Cited by 37
Wang, P., Lau, S.-Y., Deng, S., Chen, P., Mok, B. W.-Y., Zhang, J., Lee, A. C.-Y., Chan, K., Tam, R. C.-Y., Xu, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23166-0 · Cited by 37
Different T cell related immunological profiles in COVID-19 patients compared to healthy controls
Khesht, A. M. S., Karpisheh, V., Saeed, B. Q., Zekiy, A. O., Yapanto, L. M., Nabi‐Afjadi, M., Aksoun, M., Esfahani, M. N., Aghakhani, F., Movahed, M., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107828 · Cited by 37
Jing, X., Xu, M., Song, D., Yue, T., Wang, Y., Zhang, P., Zhong, Y., Zhang, M., Lam, T. T., Faria, N. R., et al. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00271-2 · Cited by 39
Wang, M., Chang, W., Zhang, L., & Zhang, Y. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.77561 · Cited by 35
Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids
Miao, Y., Fan, L., & Li, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01445 · Cited by 36
Can Natural Killer Cells Be a Principal Player in Anti-SARS-CoV-2 Immunity?
Ahmed, F. N., Jo, D., & Lee, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.586765 · Cited by 36
Xie, M., Yunis, J., Yao, Y., Shi, J. C., Yang, Y., Zhou, P., Liang, K., Wan, Y., Mehdi, A. M., Chen, Z., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1251 · Cited by 36
Siemińska, I., Węglarczyk, K., Surmiak, M., Kurowska-Baran, D., Sanak, M., Siedlar, M., & Baran, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748097 · Cited by 39
Khoo, W. H., Jackson, K., Phetsouphanh, C., Zaunders, J., Alquicira-Hernández, J., Yazar, S., Ruiz‐Diaz, S., Singh, M., Dhenni, R., Kyaw, W., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109209 · Cited by 31
NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19
Bergantini, L., d’Alessandro, M., Cameli, P., Cavallaro, D., Gangi, S., Cekorja, B., Sestini, P., & Bargagli, E. (2021) · Cells · doi:10.3390/cells10113182 · Cited by 34
Rausch, L., Lutz, K., Schifferer, M., Winheim, E., Gruber, R., Oesterhaus, E. F., Rinke, L., Hellmuth, J. C., Scherer, C., Muenchhoff, M., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12173 · Cited by 31
Innate Immune Response in SARS-CoV-2 Infection
Schiuma, G., Beltrami, S., Bortolotti, D., Rizzo, S., & Rizzo, R. (2022) · Microorganisms · doi:10.3390/microorganisms10030501 · Cited by 39
Genetic and phenotypic analysis of the causal relationship between aging and COVID-19
Ying, K., Zhai, R., Pyrkov, T. V., Shindyapina, A. V., Mariotti, M., Fedichev, P. O., Shen, X., & Gladyshev, V. N. (2021) · Communications Medicine · doi:10.1038/s43856-021-00033-z · Cited by 37
Perspective of HLA-G Induced Immunosuppression in SARS-CoV-2 Infection
Lin, A., & Yan, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.788769 · Cited by 33
Early Response of CD8+ T Cells in COVID-19 Patients
Ramljak, D., Vukoja, M., Ćurlin, M., Vukojević, K., Barbarić, M., Glamočlija, U., Purisevic, B., Perić, O., & Šoljić, V. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121291 · Cited by 33
Владимирович, Б. М., Klypa, T. V., Аркадьевна, М. И., Yusubalieva, G. M., Baklaushev, V. P., Kolyshkina, N. A., & Troitsky, A. V. (2022) · Scientific Reports · doi:10.1038/s41598-022-22045-y · Cited by 34
Rasmi, Y., Jalali, L., Khalid, S., Shokati, A., Tyagi, P., Öztürk, A., & Nasimfar, A. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156253 · Cited by 33
Yang, J., Zhong, M., Zhang, E., Hong, K., Yang, Q., Zhou, D., Xia, J., Chen, Y.-Q., Sun, M., Zhao, B., et al. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab014 · Cited by 32
Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework
Kumar, N., Admane, N., Kumari, A., Sood, D., Grover, S., Prajapati, V. K., Chandra, R., & Grover, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-86986-6 · Cited by 30
Guglielmelli, P., Mazzoni, A., Maggi, L., Kiros, S. T., Zammarchi, L., Pilerci, S., Rocca, A., Spinicci, M., Borella, M., Bartoloni, A., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26305 · Cited by 30
Self-citationSahebnasagh, A., Nabavi, S. M., Kashani, H. R. K., Aghaabdollahian, S., Habtemariam, S., & Rezabakhsh, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108257 · Cited by 31
NK cell subsets and dysfunction during viral infection: a new avenue for therapeutics?
Bjorgen, J. C., Dick, J. K., Cromarty, R. T., Hart, G. T., & Rhein, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267774 · Cited by 30
T cell phenotypes in COVID-19 - a living review
Hanna, S. J., Codd, A. S., Gea‐Mallorquí, E., Scourfield, D. O., Richter, F. C., Ladell, K., Borsa, M., Compeer, E. B., Moon, O. R., Galloway, S. A. E., et al. (2020) · Oxford Open Immunology · doi:10.1093/oxfimm/iqaa007 · Cited by 29
Belaid, B., Mahammed, L. L., Mihi, B., Rahali, S. Y., Djidjeli, A., Larab, Z., Berkani, L., Berkane, I., Sayah, W., Merah, F., et al. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.4cova1020-703r · Cited by 29
Theoharides, T. C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090860 · Cited by 29
Kassianidis, G., Siampanos, A., Poulakou, G., Adamis, G., Rapti, A., Milionis, H. J., Dalekos, G. Ν., Petrakis, V., Sympardi, S., Metallidis, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094894 · Cited by 29
Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
Zhu, Q., Xu, Y., Wang, T., & Xie, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1053437 · Cited by 32
A gendered magnifying glass on COVID-19
Salvati, L., Biagioni, B., Vivarelli, E., & Parronchi, P. (2020) · Clinical and Molecular Allergy · doi:10.1186/s12948-020-00129-2 · Cited by 31
Self-citationWang, X., Huang, K. L., Jiang, H., Hua, L., Yu, W., Ding, D., Wang, K., Li, X., Zou, Z., Jin, M., et al. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00308-0 · Cited by 28
COVID-19: The Emerging Immunopathological Determinants for Recovery or Death
Ahmad, T., Chaudhuri, R., Joshi, M. C., Almatroudi, A., Rahmani, A. H., & Ali, S. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.588409 · Cited by 30
Chen, Q., Yu, B., Yang, Y., Huang, J., Liang, Y., Zhou, J., Li, L., Peng, X., Cheng, B., & Lin, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107685 · Cited by 29
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients
Martín‐Sánchez, E., Garcés, J., Maia, C., Inogés, S., de Cerio, A. L.-D., Carmona-Torre, F., Marín‐Oto, M., Alegre, F., Molano, E., Fernández-Alonso, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.659018 · Cited by 29
Exploring the Utility of NK Cells in COVID-19
Deng, X., Terunuma, H., & Nieda, M. (2022) · Biomedicines · doi:10.3390/biomedicines10051002 · Cited by 27
Tsilioni, I., & Theoharides, T. C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03493-7 · Cited by 29
Manickam, C., Sugawara, S., & Reeves, R. K. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008820 · Cited by 27
Huang, S., Zhao, S., Luo, H., Wu, Z., Wu, J., Xia, H., & Chen, X. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01479-6 · Cited by 28
Edible and Herbal Plants for the Prevention and Management of COVID-19
Li, S., Cheng, C., Zhang, C., Tang, G., Tan, H., Chen, H., Wang, N., Lai, A. Y. K., & Feng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.656103 · Cited by 28
Myeloid cells in COVID-19 microenvironment
Qin, G., Liu, S., Li, Y., Yu, W., & Zhang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00792-0 · Cited by 27
Casado, J. L., Moraga, E., Vizcarra, P., Velasco, H., Martín-Hondarza, A., Häemmerle, J., Gómez, S., Quereda, C., & Vallejo, A. (2021) · Viruses · doi:10.3390/v14010046 · Cited by 27
Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes
Sabbatinelli, J., Matacchione, G., Giuliani, A., Ramini, D., Rippo, M. R., Procopio, A. D., Bonafè, M., & Olivieri, F. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111667 · Cited by 28
Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors
Rovito, R., Augello, M., Ben-Haim, A., Bono, V., Monforte, A. D., & Marchetti, G. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912336 · Cited by 27
COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens
Raj, S., Bruce, A. W., Anbalagan, M., Srinivasan, H., Chinnappan, S., Rajagopal, M. S., Khanna, K., Chandramoorthy, H. C. K., & Mani, R. R. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1384939 · Cited by 26
No Small Matter: A Perspective on Nanotechnology-Enabled Solutions to Fight COVID-19
Jones, G. W., Monopoli, M. P., Campagnolo, L., Pietroiusti, A., Tran, L., & Fadeel, B. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0286 · Cited by 28
Matute, J. D., Finander, B., Pépin, D., Ai, X., Smith, N. P., Li, J. Z., Edlow, A. G., Villani, A., Lerou, P. H., & Kalish, B. T. (2021) · Pediatric Research · doi:10.1038/s41390-021-01793-z · Cited by 26
Immune profiling of COVID-19: preliminary findings and implications for the pandemic
Maecker, H. T. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002550 · Cited by 26
Patel, S., & Wadhwa, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111785 · Cited by 27
Perforin, COVID‐19 and a possible pathogenic auto‐inflammatory feedback loop
Cunningham, L., Kimber, I., Basketter, D. A., Peter Simmonds, K., McSweeney, S. M., Tziotzios, C., & McFadden, J. P. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13102 · Cited by 27
Morrell, E. D., Bhatraju, P. K., Sathe, N. A., Lawson, J. J., Mabrey, L., Holton, S. E., Presnell, S., WIEDEMAN, A. E., Acosta‐Vega, C., Mitchem, M. A., et al. (2022) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00049.2022 · Cited by 26
Long COVID Definition, Symptoms, Risk Factors, Epidemiology and Autoimmunity: A Narrative Review
Kozłowski, P., Leszczyńska, A., & Ciepiela, O. (2024) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2024.100068 · Cited by 27
Manifestations and mechanisms of central nervous system damage caused by SARS-CoV-2
Yang, F., Zhao, H., Liu, H., Wu, X., & Li, Y. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.09.015 · Cited by 24
Gupta, S., Agrawal, S., Sandoval, A., Su, H., Tran, M., & Demirdağ, Y. Y. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01256-y · Cited by 25
Yu, S., Di, C., Chen, S., Guo, M., Yan, J., Zhu, Z., Liu, L., Feng, R., Xie, Y., Zhang, R., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00562-1 · Cited by 24
An Overview on the Epidemiology and Immunology of COVID-19
Meskini, M., Rami, M. R., Maroofi, P., Ghosh, S. B., Siadat, S. D., & Sheikhpour, M. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.07.021 · Cited by 28
Differential dynamics of peripheral immune responses to acute SARS-CoV-2 infection in older adults
Lewis, S. A., Sureshchandra, S., Zulu, M. Z., Doratt, B. M., Jankeel, A., Ibraim, I. C., Pinski, A. N., Rhoades, N. S., Curtis, M., Jiang, X., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00127-2 · Cited by 23
Dutt, T. S., LaVergne, S. M., Webb, T. L., Baxter, B. A., Stromberg, S., McFann, K., Berry, K., Tipton, M., Alnachoukati, O., Zier, L., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100830 · Cited by 24
Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery
Ruenjaiman, V., Sodsai, P., Kueanjinda, P., Bunrasmee, W., Klinchanhom, S., Reantragoon, R., Tunvirachaisakul, C., Manothummetha, K., Mejun, N., Liengswangwong, K., et al. (2022) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.09.001 · Cited by 22
Tsilioni, I., & Theoharides, T. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119487 · Cited by 24
Zhang, M., Zheng, R., Liu, W., Hou, J.-L., Yang, Y., & Shang, H. (2023) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2023.08.004 · Cited by 25
The immune system view of the coronavirus SARS-CoV-2
Celardo, I., Pace, L., Cifaldi, L., Gaudio, C., & Barnaba, V. (2020) · Biology Direct · doi:10.1186/s13062-020-00283-2 · Cited by 23
SARS-CoV-2 infection paralyzes cytotoxic and metabolic functions of the immune cells
Singh, Y., Trautwein, C., Fendel, R., Krickeberg, N., Berezhnoy, G., Bissinger, R., Ossowski, S., Salker, M. S., Casadei, N., Rieß, O., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e07147 · Cited by 24
Immunosuppression as a Hallmark of Critical COVID-19: Prospective Study
Kalicińska, E., Szymczak, D., Zińczuk, A., Adamik, B., Śmiechowicz, J., Skalec, T., Nowicka‐Suszko, D., Biernat, M., Bogucka‐Fedorczuk, A., Rybka, J., et al. (2021) · Cells · doi:10.3390/cells10061293 · Cited by 24
Chu, C.-F., Sabath, F., Fibi-Smetana, S., Sun, S., Öllinger, R., Noeßner, E., Chao, Y.-Y., Rinke, L., Winheim, E., Rad, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.601080 · Cited by 23
Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy
Smith, P. L., Piadel, K., & Dalgleish, A. G. (2021) · Vaccines · doi:10.3390/vaccines9121392 · Cited by 24
Generation of Cytotoxic T Cells and Dysfunctional CD8 T Cells in Severe COVID-19 Patients
Gozzi-Silva, S. C., Oliveira, L. D. M., Alberca, R. W., Pereira, N. Z., Yoshikawa, F. S. Y., Pietrobon, A. J., Yendo, T. M., Andrade, M. M. D. S., Ramos, Y. Á. L., de Brito, C. A., et al. (2022) · Cells · doi:10.3390/cells11213359 · Cited by 23
NK cells in COVID-19—from disease to vaccination
Hammer, Q., Cuapio, A., Bister, J., Björkström, N. K., & Ljunggren, H. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad031 · Cited by 25
Blanco‐Rodríguez, R., Du, X., & Hernandez-Vargas, E. A. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.106412 · Cited by 23
Chen, J., & Vitetta, L. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab061 · Cited by 23
T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination
Notarbartolo, S. (2024) · Vaccines · doi:10.3390/vaccines12101126 · Cited by 23
Pattern Recognition Proteins: First Line of Defense Against Coronaviruses
Labarrere, C. A., & Kassab, G. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652252 · Cited by 22
Sala, L. L., Gandini, S., Bruno, A., Allevi, R., Gallazzi, M., Senesi, P., Palano, M. T., Meregalli, P., Longhi, E., Sommese, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.798813 · Cited by 23
Albayrak, N., Cano, C. O., Karimi, S., Dogahe, D., Praet, A. V., Godefroid, A., del Mármol, V., Grimaldi, D., Bondue, B., Vooren, J. V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.769839 · Cited by 22
Natural killer cells for antiviral therapy
Smith, D. M., Schafer, J. R., Tullius, B. P., Witkam, L., & Paust, S. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abl5278 · Cited by 22
Immune response to COVID-19 infection: a double-edged sword
Saad, N. M., & Moussa, S. (2021) · Immunological Medicine · doi:10.1080/25785826.2020.1870305 · Cited by 21
Obuchowska, A., Standyło, A., Obuchowska, K., Kimber-Trojnar, Ż., & Leszczyńska‐Gorzelak, B. (2021) · Biomolecules · doi:10.3390/biom11081202 · Cited by 22
Mori, S., Ai, T., & Otomo, Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239644 · Cited by 20
Jiménez‐Cortegana, C., Liró, J., Carrión, N. P., Salamanca, E., Sojo-Dorado, J., de la Cruz‐Merino, L., Pascual, Á., Rodríguez‐Baño, J., & Sánchez‐Margalet, V. (2021) · Viral Immunology · doi:10.1089/vim.2021.0044 · Cited by 20
橋本, 章., Kitajima, H., Arai, T., Tamura, Y., Arai, T., Morishita, H., Matsuoka, H., Han, Y., Minamoto, S., Hirashima, T., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.734838 · Cited by 20
Metadata
- Authors
- Mazzoni, A., Salvati, L., Maggi, L., Capone, M., Vanni, A., Spinicci, M., Mencarini, J., Caporale, R., Peruzzi, B., Antonelli, A., Trotta, M., Zammarchi, L., Ciani, L., Gori, L., Lazzeri, C., Matucci, A., Vultaggio, A., Rossi, O., Almerigogna, F., Parronchi, P., Fontanari, P., Lavorini, F., Peris, A., Rossolini, G. M., Bartoloni, A., Romagnani, S., Liotta, F., Annunziato, F., & Cosmi, L.
- Affiliations
- University of Florence (IT)
- Corresponding author
- Annunziato, Francesco
- ORCID
- Mazzoni, Alessio
- Salvati, Lorenzo
- Maggi, Laura
- Capone, Manuela
- Vanni, Anna
- Spinicci, Michele
- Mencarini, Jessica
- Peruzzi, Benedetta
- Antonelli, Alberto
- Trotta, Michele
- Zammarchi, Lorenzo
- Gori, Leonardo
- Lazzeri, Chiara
- Matucci, Andrea
- Vultaggio, Alessandra
- Parronchi, Paola
- Lavorini, Federico
- Peris, Adriano
- Bartoloni, Alessandro
- Liotta, Francesco
- Annunziato, Francesco
- Cosmi, Lorenzo
- Venue
- Journal of Clinical Investigation
- Published
- 2020-08-04
- Volume
- 130
- Issue
- 9
- Pages
- 4694-4703
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7456250
- OpenAlex
- W3032533580
- Cited by
- 502
- References
- 45
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 47 · 2023: 70 · 2022: 105 · 2021: 181 · 2020: 70
- FWCI
- 14.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Funders
- Università degli Studi di Firenze
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- COVID-19 pandemic, SARS-CoV-2, interleukin-6, natural killer cells, CD8+ T cells, CD4+ T cells, granzyme A, T cell senescence, tocilizumab, cytokine storm, acute respiratory distress syndrome, intensive care
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, B-Lymphocytes, Critical Care, Cytotoxicity, Immunologic, Female, Humans, Killer Cells, Natural, Male, Middle Aged, Pneumonia, Viral, CD4-Positive T-Lymphocytes, Interleukin-6, Cytokines, Coronavirus Infections, CD8-Positive T-Lymphocytes, Models, Immunological, Granzymes, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
